Compare MasTec Inc (MTZ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs Viatris Inc — how do they compare? MasTec Inc trades at $283.44 (market cap $21.90B), while Viatris Inc trades at $16.14 (market cap $18.69B). The key difference: MasTec Inc is the larger of the two by market cap, and Viatris Inc pays a 2.95% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MTZ | VTRS | |
|---|---|---|
Market Cap | $21.90B | $18.69B |
Sector | Technology | Health |
52-Week High | $437.51 | $17.86 |
52-Week Low | $172.51 | $9.49 |
Enterprise Value | $24.81B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTZ trades at $282.66, up 5.36% over 24 hours, with a bearish technical signal but strong fundamental momentum. The company reported record Q2 2026 revenue of $4.37 billion, up 23% year-over-year, and raised its full-year outlook, supported by a $21.4 billion backlog and recent acquisition of The Superior Group. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show selling pressure near resistance at $283.
The outlook for MTZ is positive, driven by infrastructure demand and earnings beats, but risks include execution on large projects and debt from recent note issuance. The stock offers growth potential if it can sustain margin expansion and capitalize on its record backlog, though investors should monitor communications segment delays and interest expense impacts.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
